Physician profile
Efrain Gonzalez-Arroyo
NPI 1710078704
$7,236.04
in general payments reported to CMS, 2019-2025
21 companies · $1,488 in 2025
The $1,488 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $795 · 2020: $780 · 2021: $897 · 2022: $961 · 2023: $834 · 2024: $1,480 · 2025: $1,488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,778 · Education: $24.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,777.87 |
| Education | $24.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $968.73 | 2019-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $868.83 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $812.06 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $688.88 | 2019-2025 | Lokelma, Farxiga |
| Bayer Puerto Rico INC. | $671.39 | 2023-2025 | Kerendia |
| Eli Lilly Export S.A. Puerto Rico Branch | $538.86 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $390.43 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $374.51 | 2019-2023 | |
| Amgen INC. | $344.40 | 2019-2025 | Evenity, Repatha, Prolia |
| Merck Sharp & Dohme LLC | $327.66 | 2019-2023 | Janumet, Steglujan, Segluromet |
| Dexcom, INC. | $239.36 | 2021-2025 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $205.15 | 2019-2024 | Eliquis |
| Janssen Pharmaceuticals, INC | $174.74 | 2019-2021 | |
| Corcept Therapeutics | $129.74 | 2024-2025 | Korlym |
| Lilly USA, LLC | $118.71 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $90.28 | 2020-2025 | Tymlos |
| Novartis Pharmaceuticals Corporation | $70.38 | 2025 | |
| Abbvie INC. | $65.00 | 2020-2025 | |
| Pbg Puerto Rico LLC | $60.24 | 2019-2021 | |
| Medtronic, INC. | $49.58 | 2023 | Linq II |
| Boston Scientific Corporation | $47.11 | 2024 | Greenlight Xps |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Efrain Gonzalez-Arroyo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.